Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRSS1 | P07477 | 10/20 | 0.81 |
| ▸ | F2 | P00734 | 6/20 | 0.74 |
| ▸ | PRSS2 | P07478 | 2/20 | 0.74 |
| ▸ | PRSS3 | P35030 | 2/20 | 0.74 |
| ▸ | PLG | P00747 | 1/20 | 0.74 |
| ▸ | C1S | P09871 | 1/20 | 0.74 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29079516 | 0.94 | PRSS1 (0.85) | PRSS1F2PRSS2PRSS3PLG | |
| Hydrochloric Acid SCHEMBL29027359 | 0.92 | PRSS1 (0.85) | PRSS1F2PRSS2PRSS3PLG | |
| Hydrochloric Acid SCHEMBL30400933 | 0.92 | PRSS1 (0.85) | PRSS1F2PRSS2PRSS3PLG | |
| SCHEMBL13901353 | 0.92 | PRSS1 (0.78) | PRSS1F2PRSS2PRSS3PLG | |
| SCHEMBL14599539 | 0.88 | PRSS1 (1.00) | PRSS1F2PRSS2PRSS3PLG | |
| SCHEMBL12989513 | 0.88 | PRSS1 (1.00) | PRSS1F2PRSS2PRSS3PLG | |
| SCHEMBL14599537 | 0.88 | PRSS1 (1.00) | PRSS1F2PRSS2PRSS3PLG | |
| SCHEMBL14599540 | 0.86 | PRSS1 (0.88) | PRSS1F2PRSS2PRSS3PLG | |
| SCHEMBL19430950 | 0.84 | PRSS1 (0.59) | PRSS1F2PLG | |
| SCHEMBL12989612 | 0.84 | PRSS1 (0.90) | PRSS1F2PRSS2PRSS3PLG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090156601-A1 | PYRIMIDINE DERIVATIVES FOR THE TREATMENT OF CANCER | F. HOFFMANN-LA ROCHE AG (CH) | 2009-06-18 | — | — | US | disclosed |
| WO-2007042806-A1 | PYRIMIDINE DERIVATIVES FOR THE TREATMENT OF CANCER | LUDWIG INSTITUTE FOR CANCER RESEARCH (CH) | 2007-04-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090156601-A1 | PYRIMIDINE DERIVATIVES FOR THE TREATMENT OF CANCER | NR3C1, NR4A3, NR4A1 | PRSS1 2548/4885F2 3394/4885PRSS2 3769/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.